My Treatment Approach: Interpreting the Data for Early-Stage HR+ Breast Cancer

In this series, we will discuss recent advances in the treatment of HR+ breast cancer. We will review two patient cases and discuss our treatment approach to illustrate how we are incorporating recent trial data into our clinical practice.

EP. 11: Risk of Recurrence

August 3rd 2023

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

EP. 12: Key Findings from the NATALEE Trial

August 3rd 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

EP. 13: Impact of Trial Data on Clinical Practice

August 10th 2023

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

EP. 14: Managing Toxicities and Adverse Events of CDK 4/6 Inhibitors

August 10th 2023

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

EP. 15: What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?

August 17th 2023

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.